Basilea provides a timely reminder of the ongoing robust performance of the existing anti-infectives portfolio, along with a summary of plans for 2024.
05 Jan 2024
Basilea portfolio update
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Basilea portfolio update
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
05 Jan 2024 -
Author:
Brian White | Andrew Keith -
Pages:
2 -
Basilea provides a timely reminder of the ongoing robust performance of the existing anti-infectives portfolio, along with a summary of plans for 2024.